

Premier Health Insuring Corporation

POLICY AND PROCEDURE MANUAL

Policy Number: PA.095.PC
Last Review Date: 09/10/2015
Effective Date: 01/01/2016
Renewal Date: 01/01/2017

PA.095.PC – Pancreatectomy with Autologous Islet Cell Transplantation

This policy applies to the following line(s) of business:

- ✓ Premier Health Insuring Corporation MA – DSNP

Premier Health Insuring Corporation considers Pancreatectomy with Autologous Islet Cell Transplantation medically necessary for the following indications:

1. Chronic pancreatitis with intractable pain; or
2. Acute relapsing pancreatitis (ARP) with episodes that are frequent, disruptive and persist over time; or
3. Intractable pain from other confirmed benign disease of the pancreas including pancreatic pseudocysts, cystic neoplasms (e.g. intrapapillary mucinous neoplasms IPMN), insulinomas, or neuroendocrine and other tumors.
And
4. Other treatments have failed to adequately control symptoms including:
 - a. Conservative medical therapy including pain management and dietary modifications and/or
 - b. Endoscopic drainage and/or stenting of pancreatic ducts (or the member is not a candidate for this treatment) and/or
5. Intractable pain from other confirmed benign disease of the pancreas including pseudocysts, cystic neoplasms, insulinomas, or neuroendocrine tumors.
And
And
6. The member is in need of a total pancreatectomy, or partial pancreatectomy with possibility of future complete pancreatectomy
And
7. The member is non-diabetic at the time of pancreatectomy or is diabetic, but the C-peptide level demonstrates evidence of beta cell function as stable

Note: If the member does not require insulin pre- pancreatectomy, C-peptide levels are not needed to confirm there is beta cell function

Limitations

Islet Cell extraction for Auto-transplantation can be performed only in facilities that are Food and Drug Administration (FDA) approved for extraction of Islet cells from the Pancreas.

PA.095.PC – Pancreatectomy with Autologous Islet Cell Transplantation

Policy Number: PA.095.PC
Last Review Date: 09/10/2015
Effective Date: 01/01/2016
Renewal Date: 01/01/2017

Experimental and Investigational and therefore not covered for chronic pancreatitis:

- Allogeneic Islet Cell Transplant
- Xenogeneic Islet Cell Transplant (all xenogeneic transplants are considered experimental and investigational)
- All other indications not listed in this policy.

Background

Chronic pancreatitis is the inflammation of the pancreas that worsens with time ultimately leading to the destruction of the gland. It can lead to exocrine pancreatic insufficiency and diabetes. Treatment options include pain management and dietary modifications initially, but chronic and recurrent episodes may lead to a autologous islet cell transplantation.

A typical islet cell transplant requires over 500,000 islet cells, but varies depending on the recipient's weight. One of the desired patient outcomes is insulin independence. Elimination of clinically significant hypoglycemia episodes and improved glucose control are other important patient outcomes. One or more pancreata are obtained from donor(s). The islets must be removed within hours after the recovery of the donor pancreas to ensure viability. The islet cells are transplanted by injection into the portal vein of the recipient either using direct visualization, guided ultrasound or percutaneously. The islet cell transplant may be performed alone, in combination with a kidney transplant, or after a kidney transplant. Islet recipients require immunosuppressant therapy to prevent rejection of the transplanted islet cells. Routine follow-up care is necessary for each trial participant.

One of the goals of pancreatectomy with autologous islet cell transplantation is to prevent the onset of diabetes, reduce the severity of the disease, reduce the pain and ultimately improve one's quality of life.

Codes:

CPT Codes / HCPCS Codes / ICD-10 Codes	
Code	Description
48160	Pancreatectomy, total or subtotal, with autologous transplantation of pancreas or pancreatic islet cells
G0341	Percutaneous islet cell transplant, includes portal vein catheterization and infusion

PA.095.PC – Pancreatectomy with Autologous Islet Cell Transplantation

Policy Number: PA.095.PC
Last Review Date: 09/10/2015
Effective Date: 01/01/2016
Renewal Date: 01/01/2017

G0342	Laparoscopy for islet cell transplant, includes portal vein catheterization and infusion
G0343	Laparotomy for islet cell transplant, includes portal vein catheterization and infusion

References

1. Bellin MD, Carlson AM, Kobayashi T, et al. Outcome after pancreatectomy and islet autotransplantation in a pediatric population. J Pediatr Gastroenterol Nutr. 2008;47:37-44. http://ovidsp.tx.ovid.com/sp-3.15.1b/ovidweb.cgi?WebLinkFrameset=1&S=GHPAFPMMHMDDLOEPNCKKM BJCHGCKAA00&returnUrl=ovidweb.cgi%3f%26Full%2bText%3dL%257cS.sh.22.23%257c0%257c00005176-200807000-00007%26S%3dGHPAFPMMHMDDLOEPNCKKMBJCHGCKAA00&directlink=ht tp%3a%2f%2fgraphics.tx.ovid.com%2fovftpdfs%2fFPDDNCJCMBEPHM00%2ffs 046%2fovft%2flive%2fgv023%2f00005176%2f00005176-200807000-00007.pdf&filename=Outcome+After+Pancreatectomy+and+Islet+Autotransplant ation+in+a+Pediatric+Population.&pdf_key=FPDDNCJCMBEPHM00&pdf_index= /fs046/ovft/live/qv023/00005176/00005176-200807000-00007
2. Bellin MD, Freeman ML, Schwarzenberg SJ, et al. Quality of life improves for pediatric patients after total pancreatectomy and islet autotransplant for chronic pancreatitis. . [Clin Gastroenterol Hepatol](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3163759/pdf/nihms311960.pdf). 2011 Sep;9(9):793-799. doi: 10.1016/j.cgh.2011.04.024. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3163759/pdf/nihms311960.pdf>
3. Bottino R, Bertera S, Grupillo M, et al. Isolation of human islets for autologous islet cell transplantation in children and adolescents with chronic pancreatitis. J Transplant. 2012;2012:642787. doi: 10.1155/2012/642787 <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3306977/> Gaba RC, Garcia-Roca R, Oberholzer J. Pancreatic islet cell transplantation: An update for interventional radiologists. J Vasc Interv Radiol. 2012;23:583-594. http://www.sirweb.org/misc/JVIR_pancreatic_51412.pdf
4. Centers for Medicare and Medicaid Services (CMS). National Coverage Determination (NCD). No. 260.3.1 - Islet Cell Transplantation in the Context of a Clinical Trial, Effective Date: 10/1/2004 http://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCID=286&ncdver=1&DocID=260.3.1&list_type=ncd&bc=gAAAAAgAAAA&
5. Centers for Medicare and Medicaid Services (CMS). CMS Manual, Claims Processing. Pub 100-04, Transmittal 261, Change Request 3385, Date: 07-30-2004 Billing Requirements for Islet Cell Transplantation for Beneficiaries in a

PA.095.PC – Pancreatectomy with Autologous Islet Cell Transplantation

Policy Number: PA.095.PC
Last Review Date: 09/10/2015
Effective Date: 01/01/2016
Renewal Date: 01/01/2017

National Institutes of Health Clinical Trial.

<http://www.cms.hhs.gov/transmittals/downloads/R261CP.pdf>

6. Centers for Medicare and Medicaid Services (CMS). CMS Manual System. Pub 100-04, Transmittal 986, Change Request 5140. Date: June 16, 2006: Subject: Payment for Islet Cell Transplantation in NIH-Sponsored Clinical Trials. <http://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/downloads/R986CP.pdf>
7. Dunderdale J, McAuliffe JC, McNeal SF, et al. Should pancreatectomy with islet cell autotransplantation in patients with chronic alcoholic pancreatitis be abandoned? *J Am Coll Surg*. 2013 Apr; 216(4):591-596; discussion 596-598. doi: 10.1016/j.jamcollsurg.2012.12.043. http://ac.els-cdn.com/S1072751513000021/1-s2.0-S1072751513000021-main.pdf?_tid=b02369b4-b131-11e3-8b3c-00000aacb361&acdnat=1395431451_d2f7a56746939e3ba1a0c2095d7314a0
8. Issa Y, Bruno MJ, Bakker OJ, et al. Treatment options for chronic pancreatitis. *Nature Reviews Gastroenterology & Hepatology* 11, 556-564 (2014). <http://www.nature.com/nrgastro/journal/v11/n9/full/nrgastro.2014.74.html?message-global=remove>
9. Ong SL, Gravante G, Pollard CA, et al. Total pancreatectomy with islet autotransplantation: an overview. *HPB (Oxford) [J International Hepato-Pancreato-Biliary Assn]*. 2009; 11 (8):613-621. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2799613/pdf/hpb0011-0613.pdf>
10. Rodriguez Rilo HL, Ahmad SA, D'Alessio D, et al. Total pancreatectomy and autologous islet cell transplantation as a means to treat severe chronic pancreatitis." *J Gastrointest Surg*. 2003; 7(8):978-989. http://ac.els-cdn.com/S1091255X03001938/1-s2.0-S1091255X03001938-main.pdf?_tid=e77ee43a-b134-11e3-b5e9-00000aacb361&acdnat=1395432833_0ae5c29aa6e51161ba0a058710b17e65
11. Sutherland DE, Gruessner AC, Carlson AM, et al., Islet autotransplant outcomes after total pancreatectomy: a contrast to islet allograft outcomes. *Transplantation*. 2008; 86:1799-1802. http://ovidsp.tx.ovid.com/sp-3.15.1b/ovidweb.cgi?WebLinkFrameset=1&S=JPFFFPKMFCDLOGMNCKKCEMCPGDEAA00&returnUrl=ovidweb.cgi%3f%26Full%2bText%3dL%257cS.sh.22.23%257c0%257c00007890-200812270-00032%26S%3dJPFFFPKMFCDLOGMNCKKCEMCPGDEAA00&directlink=http%3a%2f%2fgraphics.tx.ovid.com%2fovftpdfs%2fFPDDNMCCEGMFC00%2ffs046%2fovft%2flive%2fgv023%2f00007890%2f00007890-200812270-00032.pdf&filename=Islet+Autotransplant+Outcomes+After+Total+Pancreatectomy%3a+A+Contrast+to+Islet+Allograft+Outcomes.&pdf_key=FPDDNMCCEGMFC00&pdf_index=/fs046/ovft/live/qv023/00007890/00007890-200812270-00032

PA.095.PC – Pancreatectomy with Autologous Islet Cell Transplantation

Policy Number: PA.095.PC

Last Review Date: 09/10/2015

Effective Date: 01/01/2016

Renewal Date: 01/01/2017

12. Sutherland DE, et al. Total Pancreatectomy and Islet Autotransplantation for Chronic Pancreatitis. Chronic Pancreatitis, Prof. David Sutherland (Ed.), ISBN: 978-953-51-0011-9, InTech, Available from:
<http://www.intechopen.com/books/chronic-pancreatitis/total-pancreatectomy-and-islet-autotransplantation-forchronic-pancreatitis>
13. The University of Chicago Medical Center: Autologous Islet Cell Transplantation, © 2015. Accessed: March 26, 2015. Available at:
<http://www.uchospitals.edu/specialties/pancreas/pancreatitis/ait.html>
14. U.S. Preventive Services Task Force: Recommendations for adults. Current as of March 2015. Accessed: 03/31/2015.
<http://www.uspreventiveservicestaskforce.org/Page/Name/recommendations>

Disclaimer:

Premier Health Insuring Corporation medical payment and prior authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. The policies constitute only the reimbursement and coverage guidelines of Premier Health Insuring Corporation and its affiliated managed care entities. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies.

Premier Health Insuring Corporation reserves the right to review and update the medical payment and prior authorization guidelines in its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.

These policies are the proprietary information of Evolent Health. Any sale, copying, or dissemination of said policies is prohibited.